CHAMPIONS ONCOLOGY, INC. (NASDAQ:CSBR) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain OfficersItem 5.02.
CHAMPIONS ONCOLOGY, INC. (NASDAQ:CSBR) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
Departure of Directors or Certain Officer; Election of Directors; Appointment of Certain Officer; Compensatory Arrangements of Certain Officers.
On November 29, 2016 Champions Oncology, Inc., (the “Company”), filed an 8-K announcing senior leadership changes whereby the Company’s Chief Executive Officer, Joel Ackerman, will shift his role and become the Chairman of the Board of Directors; Dr. David Sidransky, the founder of Champions and current Chairman of the Board of Directors, will assume the role of lead director; and, Dr. Ronnie Morris, current President of Champions, will assume the role of CEO. These changes became effective on January 20, 2017.
About CHAMPIONS ONCOLOGY, INC. (NASDAQ:CSBR)
Champions Oncology, Inc. is engaged in the development and sale of technology solutions and products to personalize the development and use of oncology drugs. The Company has two business segments: Personalized Oncology Solutions (POS) and Translational Oncology Solutions (TOS). The POS segment provides physicians and patients information to help guide the development of personalized treatment plans. The TOS segment provides services to pharmaceutical and biotechnology companies seeking personalized approaches to drug development. Its TumorGraft Technology Platform consists of processes, physical tumors and information that it uses to personalize the development and use of oncology drugs. Each tumor from patients that it has preserved for implantation in mice, along with the patient data and molecular information associated with the tumors, are known as TumorGrafts or Patient Derived XenoGrafts of PDX Models. The collection of TumorGrafts is referred to as the Company’s TumorBank. CHAMPIONS ONCOLOGY, INC. (NASDAQ:CSBR) Recent Trading Information
CHAMPIONS ONCOLOGY, INC. (NASDAQ:CSBR) closed its last trading session up +0.07 at 3.76 with 21,940 shares trading hands.
Champions Oncology, Inc. is engaged in the development and sale of technology solutions and products to personalize the development and use of oncology drugs. The Company has two business segments: Personalized Oncology Solutions (POS) and Translational Oncology Solutions (TOS). The POS segment provides physicians and patients information to help guide the development of personalized treatment plans. The TOS segment provides services to pharmaceutical and biotechnology companies seeking personalized approaches to drug development. Its TumorGraft Technology Platform consists of processes, physical tumors and information that it uses to personalize the development and use of oncology drugs. Each tumor from patients that it has preserved for implantation in mice, along with the patient data and molecular information associated with the tumors, are known as TumorGrafts or Patient Derived XenoGrafts of PDX Models. The collection of TumorGrafts is referred to as the Company’s TumorBank. CHAMPIONS ONCOLOGY, INC. (NASDAQ:CSBR) Recent Trading Information
CHAMPIONS ONCOLOGY, INC. (NASDAQ:CSBR) closed its last trading session up +0.07 at 3.76 with 21,940 shares trading hands.